Krystal Biotech (KRYS) CAO trades 12,500 shares in 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Krystal Biotech Chief Accounting Officer Kathryn Romano reported exercising stock options for 12,500 shares of common stock at an exercise price of $63.55 per share on February 9, 2026, then selling the same 12,500 shares in multiple open‑market trades at prices between $270.010 and $277.88 per share. Following these sales, she directly owned 18,568 shares of Krystal Biotech common stock.
The option exercise, share sales, and a 750‑share bona fide gift to a charitable donor‑advised fund were carried out under a pre‑arranged Rule 10b5‑1 trading plan that began on November 6, 2025 and is scheduled to run through August 31, 2026, subject to earlier termination under its terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 12,500 shares ($3,401,705)
Net Sell
10 txns
Insider
ROMANO KATHRYN
Role
Chief Accounting Officer
Sold
12,500 shs ($3.40M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Exercise | Common Stock | 12,500 | $63.55 | $794K |
| Sale | Common Stock | 2,000 | $270.5579 | $541K |
| Sale | Common Stock | 5,700 | $271.6627 | $1.55M |
| Sale | Common Stock | 2,824 | $272.5079 | $770K |
| Sale | Common Stock | 928 | $273.7075 | $254K |
| Sale | Common Stock | 552 | $274.6388 | $152K |
| Sale | Common Stock | 400 | $275.68 | $110K |
| Sale | Common Stock | 96 | $277.88 | $27K |
| Gift | Common Stock | 750 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 12,500 shares (Direct);
Common Stock — 31,818 shares (Direct)
Footnotes (1)
- The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. The transaction was executed in multiple trades ranging from $270.010 to $270.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $271.105 to $272.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $272.1275 to $273.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $273.160 to $274.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $274.305 to $274.815. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $275.445 to $275.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in a single trade. Represents a bona fide gift of the Company's common stock to a charitable donor-advised fund. The options vested ratably over a four-year period beginning on February 28, 2022.
FAQ
What insider transaction did Krystal Biotech (KRYS) report for Kathryn Romano?
Kathryn Romano, Krystal Biotech’s Chief Accounting Officer, exercised options for 12,500 common shares at $63.55 per share and sold those shares in the open market. The trades occurred on February 9, 2026, at prices between $270.010 and $277.88 per share.
Was the Krystal Biotech (KRYS) insider sale by Kathryn Romano under a 10b5-1 plan?
Yes. The option exercise and share sales were executed under a Rule 10b5‑1 trading plan adopted by Kathryn Romano. The plan began on November 6, 2025 and is scheduled to terminate on August 31, 2026, subject to earlier termination as described.
What stock option activity did the Krystal Biotech (KRYS) Form 4 show?
The filing shows exercise of a stock option (right to buy) for 12,500 shares of common stock at an exercise price of $63.55 per share. The option vested ratably over four years beginning on February 28, 2022, and expires on February 27, 2032.
Did the Krystal Biotech (KRYS) insider make any gifts of stock in this Form 4?
Yes. The Form 4 reports a bona fide gift of 750 shares of Krystal Biotech common stock, coded as a G transaction. The shares were donated to a charitable donor‑advised fund, reducing Kathryn Romano’s direct holdings accordingly.